Project Grant HT94252310708
Award Date
8/1/23
Completion Date
7/31/27
Dollars Obligated
$1.8M
Federal Agency
Defense Health Agency
Awardee
Vaxsyna, Inc. (EZB7XANUD2A3)
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Franklin, NH 03235, USA
Similar Awards
This $59,956,646 Cooperative Agreement, awarded on August 27, 2024 by the National Institutes of Health (NIH) under the Advanced Research Projects Agency for Health (ARPA-H) program (CFDA 93.384), funds the development of universal vaccine design approaches for herpesviruses. The project aims to apply innovative AI-based computational methods to design stabilized antigens and protein nanoparticle vaccines that can broadly protect against human herpesviruses like HSV-1, HSV-2, and EBV. The...
The U.S. Defense Health Agency awarded a $1,354,543 Project Grant to The University of Texas MD Anderson Cancer Center to conduct a Phase 1 clinical trial of an engineered oncolytic herpes simplex virus-1 (HSV-1) M032 in newly diagnosed diffuse midline glioma patients. The award is funded under the Military Medical Research and Development (CFDA 12.420) program, which supports advanced biomedical research initiatives focused on transforming healthcare for military service members and the broader...
This $4,728,039 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) funds Hbvtech, L.L.C., a minority-owned and self-certified small disadvantaged business, to develop a new antiviral treatment regimen for the durable elimination of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) in chronic HBV infections. The award period is from July 1, 2025 to June 30, 2029. Through this funding, Hbvtech will leverage its...
The Department of the Army Medical Command awarded Invvax, Inc. a $1,878,970 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to support research titled "Invariance Mapping of the Complete HBV Genome and Testing of MRE11 Repair Nuclease Toward the Improvement of CRISPR/Cas Therapy for Hepatitis B." The period of performance is from September 1, 2022 to August 31, 2026. Under this award, Invvax will conduct research to map the complete genome of...
This $300,387 Project Grant was awarded on February 1, 2025 by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to Twilight Bioscience, Inc. located in Topsfield, MA. The objective of this 2-year grant is to develop an Fc-fusion vaccine to treat frontotemporal dementia using an integrated precision immunology approach. The award supports advanced biomedical research initiatives focused on transforming healthcare for military service members...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $236,292 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to Tufts University School of Medicine to capture and characterize the structural complexes of the herpes simplex virus (HSV) glycoproteins critical for viral entry. The project aims to use new methods to isolate and analyze the 3D structures of the GD/GH/GL and GH/GL/GB glycoprotein complexes involved in HSV cell entry, which have been...
This is a Cooperative Agreement awarded by the Uniformed Services University of the Health Sciences under the Uniformed Services University Medical Research Projects program (CFDA 12.750). The $581,940 award to The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. will evaluate the incidence of herpes zoster and response to the recombinant zoster vaccine following COVID-19 vaccination/infection, as well as assess the durability and safety of the vaccine response in...
This Cooperative Agreement award of $62,208,274.00, provided by the Advanced Research Projects Agency for Health (ARPA-H), aims to accelerate biomedical and health breakthroughs through the STRATEGIC HERPESVIRUS IMMUNE EVASION AND LATENCY DEFENSE (SHIELD) project. The award supports the development of an integrated computational toolkit for antigen engineering to transform vaccine development against important human herpes viruses. Key activities include designing and optimizing novel chimeric...
The U.S. Defense Health Agency awarded a $7,349,780 Project Grant to the University of Massachusetts Medical School (UMass Medical) to conduct research on "RNA Therapeutics for Infectious Diseases: Viral Hemorrhagic Fever" over a 4-year period from September 1, 2023 to August 31, 2027. This grant is funded through the Department of Defense's Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to develop innovative medical solutions for...
This Project Grant from the Defense Health Agency provides $734,781 to Formation Venture Engineering Foundry Inc. for precision medicine immunotherapy research under the Military Medical Research and Development program (CFDA 12.420). The research aims to develop medical solutions for treating neurodegeneration in amyotrophic lateral sclerosis patients who test positive for human endogenous retrovirus K. The awardee will conduct applied and advanced biomedical research from June 2023 through...